3 May 2016 - Ferring Pharmaceuticals today announced that Nocdurna (desmopressin) has received approval in the EU for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.

Specifically developed to reduce the amount of urine the kidneys produce, Nocdurna once-daily lyophilisate tablets are administered sublingually (without the need for water) in gender specific low doses, tailored specifically for men (50 mcg) and women (25 mcg).

Nocdurna was reviewed via the decentralised procedure with the Swedish Medical Products Agency acting as the reference member state. The majority of the EU countries were involved as concerned member states and they will have 30 days to issue a national approval. Product labelling has been agreed by all countries participating in the procedure who will issue their own local Marketing Authorisations.

For more details, go to: https://www.ferring.com/en/media/press-releases/2016/ferring-pharmaceuticals-announces-approval-for-nocdurna/